Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Bile Duct Neoplasms 3Stomach Neoplasms 2Pancreatic Neoplasms 2Neoplasms 2Esophageal Neoplasms 2Colorectal Neoplasms 2Venous Thromboembolism 1Supratentorial Neoplasms 1Sigmoid Neoplasms 1Recurrence 1Rectal Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Glioma 1Gallbladder Neoplasms 1Erectile Dysfunction 1Endometrial Neoplasms 1Dyskinesias 1Diarrhea 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Gemcitabine 39Cisplatin 24Oxaliplatin 21Capecitabine 20Fluorouracil 11Leucovorin 9Irinotecan 9130-nm albumin-bound paclitaxel 8durvalumab 6Taxes 5Radiotherapy 5Platinum 4Immunohistochemistry 4Erlotinib Hydrochloride 4Docetaxel 4Carboplatin 4Bevacizumab 4Albumin-Bound Paclitaxel 41,2-diaminocyclohexaneplatinum II citrate 4trifluridine tipiracil drug combination 3Trastuzumab 3Sorafenib 3Observation 3Epirubicin 3Drug Therapy 3tremelimumab 2toripalimab 2regorafenib 2pembrolizumab 2anlotinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Gallbladder Neoplasms × Long-Term Synaptic Depression × Clear all
NCT04183712 2024-10-16

Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA

Shanghai Jiao Tong University School of Medicine

Phase 2 Recruiting
102 enrolled
Gastrointestinal

Gallbladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡